CD19-targeted T-cell engagers represent a powerful therapeutic modality for B-cell depletion in oncology and autoimmune indications. Conventional bispecific antibody manufacturing faces a significant hurdle known as the chain mispairing problem, where the co-expression of multiple heavy and light chains leads to non-functional byproducts and complex purification requirements. Utilizing fully human heavy-chain-only antibodies (HCAbs) eliminates this light chain mismatching issue, providing a streamlined foundation for structurally versatile multispecifics.
What is a fully human heavy-chain-only antibody (HCAb), and how does it differ from a humanized VHH nanobody?
A fully human heavy-chain-only antibody (HCAb) is a therapeutic protein consisting entirely of human sequences and lacking a light chain. Fully human sequences are 100 percent human in origin, produced in vivo through natural immune selection in Harbour Mice® (transgenic mice engineered to produce fully human heavy-chain-only antibodies). In contrast, humanized antibodies rely on non-human sequences engineered to reduce immunogenicity, which still carry residual non-human residues and engineering trade-offs.
Fully human sequences are inherently compatible with human immune tolerance. Humanized sequences carry residual immunogenicity risk due to their non-human origins. Understanding the differences between a fully human vs humanized monoclonal antibody is essential, as mixing up these terms creates confusion regarding the clinical safety profile of the resulting therapeutic candidates.
How do CD19-targeted T-cell engagers function to deplete B-cells?
T-cell engagers function by creating an immune synapse between a T cell and a target cell. They bridge a surface receptor on the T cell, typically CD3, and a specific antigen on the target cell, such as CD19, bypassing natural T-cell receptor specificity. This structural arrangement triggers cytotoxic effects that lead to the targeted depletion of B-cells.
The structural and biophysical characteristics of the T-cell engager dictate the effectiveness of this immune synapse. Critical factors include the affinity for CD3, the affinity for the target antigen, and the physical distance the molecule creates between the two cells.
How do fully human HCAbs overcome the chain mispairing problem in bispecific antibody manufacturing?
Fully human HCAbs eliminate light chain mismatching by utilizing HCAb-derived single domains as building blocks for multispecific formats. Conventional hybridoma methods and traditional bispecific platforms often struggle with immense cost of goods and complex supply chains due to the need to correctly pair distinct heavy and light chains. Nona Biosciences’ HBICE® (HCAb-Based Immune Cell Engager) platform expands the structural diversity of these multispecifics while de-risking manufacturing.
|
Feature |
Conventional Bispecific Platforms |
Nona Biosciences HBICE® Platform |
|---|---|---|
|
Chain Pairing |
Prone to heavy and light chain mispairing |
Eliminates light chain mismatching |
|
Building Blocks |
Bulky dual-chain Fab regions |
Compact HCAb-derived single domains |
|
Manufacturability |
Complex purification and high cost of goods |
Streamlined production and lower cost of goods |
How does Nona Biosciences screen for CD19-specific HCAb-derived single domains?
Nona Biosciences leverages NonaCarFx™ (Nona’s CAR-based functional screening platform) to identify lead HCAb VH domains targeting novel CD19 epitopes. In one such campaign, detailed in Nona’s white paper on fully human HCAb platforms¹, HCAb Harbour Mice® immunized with a HEK293-hCD19 cell line facilitate the construction of a library in a lentiviral vector. Following the production of the lentiviral particle library, a Jurkat-NFAT-GFP reporter cell line is transduced and stimulated with CD19-overexpressing cell lines.
GFP-positive reporter cells expressing CD19-specific HCAb-derived single domains are isolated through fluorescence-activated cell sorting. After multiple rounds of enrichment, numerous unique clones with CD19 specificity are identified. Recent CD19 programs yielded 131 unique sequences, corresponding to a 60 percent positivity rate.
Additional characterization of the binding properties through ELISA, flow cytometry, and OCTET narrows the number of HCAb-derived single domains for functional screening. A recent campaign successfully narrowed the pool to 55 unique sequences for T-cell engager evaluation.
Why is affinity tuning critical for CD3 binders in T-cell engagers?
Affinity tuning of the CD3 binder module is essential to balance on-target cytotoxicity with low cytokine release. T-cell engager optimization must increase efficacy while maintaining a wide therapeutic window to prevent excessive T-cell activation. Selecting HCAb-derived single domains with fine-tuned affinity avoids dangerous cytokine release syndrome while ensuring sufficient engagement for effective tumor cell killing.
In a related HBICE® BCMA x CD3 study,² a T-cell engager containing a CD3 binder of medium affinity reaches cytotoxicity equivalent to benchmark molecules, but with significantly lower cytokine release. Specifically, optimized CD3 binders lead to the lowest TNF-α release and almost no non-specific cytotoxicity to off-target cells.
How does the Harbour Mice® platform ensure diverse epitope coverage for CD19?
All D and J human genes are present in the HCAb Harbour Mice®, supporting the production of fully human HCAbs with enhanced epitope coverage. Harbour Mice® is the original and first transgenic platform developed to produce fully human HCAbs through natural in vivo immune selection using human VH gene segments and a constant region lacking CH1. With over 20 years of optimization, including careful selection of sequences that ensure highly developable binders, the HCAb Harbour Mice® consistently deliver panels of HCAbs that recognize diverse, functionally relevant epitopes.
Epitope mapping of CD19 candidates has successfully identified clones targeting epitopes with partial or no overlap with reference T-cell engagers. Nona Biosciences’ Hu-mAtrIx™ (Nona’s AI platform for antibody lead selection and developability optimization) integrated in discovery extends this further by guiding the incorporation of developability-optimized sequences.
When should developers choose fully human HCAbs from Harbour Mice® for multispecific engineering?
Developers should choose fully human HCAbs from Harbour Mice® when building complex multispecific molecules that require high structural flexibility, low immunogenicity, and streamlined manufacturability. The compact nature of HCAb-derived single domains provides immense flexibility, allowing developers to incorporate multiple building blocks into a single simple design. This approach supports the Idea toward IND (I-to-I®) (Nona’s integrated end-to-end service pathway from ideation through IND filing) by minimizing late-stage attrition.
Partnering with Nona offers access to a clinically validated platform with a proven track record of success in T-cell engagers, TCR mimic antibodies & bispecific engineering. This validation is demonstrated by advanced clinical-stage programs like the bispecific Claudin 18.2 x CD3 molecule (AZD5863) developed in collaboration with AstraZeneca.
-
Nona Biosciences, Advancing Future Biotherapeutics that are Compact, Human, and Modular with Nona Biosciences’ Fully Human HCAb Platforms (White Paper), 2026. Link
-
Nona Biosciences, Overcoming challenges in T Cell engagers with affinity-tuned, structurally versatile HBICE® multispecific antibodies (White Paper), 2026. Link
-
Baeuerle, P. A., et al., Bispecific T-cell engagers for cancer therapy, Cancer Research, 2009. Link
-
Brinkmann, U., et al., The making of bispecific antibodies, mAbs, 2017. Link
-
Muyldermans, S., Nanobodies: natural single-domain antibodies, Annual Review of Biochemistry, 2013. Link
-
Suurs, F. V., et al., A review of bispecific antibodies and antibody constructs in oncology and indications, Pharmacology & Therapeutics, 2019. Link
-
Slaney, C. Y., et al., CARs versus biTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment, Cancer Discovery, 2018. Link
-
Viardot, A., et al., Treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia with blinatumomab, Blood, 2016. Link
